From QIBA Wiki
Revision as of 00:31, 7 March 2018 by Kevino
- Coordinating Committees, Biomarker Committees and Task Forces are encouraged to have 2 or 3 leaders who are preferably drawn from diverse backgrounds (Researchers, Clinicians, Physicists, Vendors, Regulators, etc.). If not possible, committees are permitted to have some concentration but should discuss plans to expand stakeholder representation at least annually.
- Goal: group consensus and imaging community input and endorsement on major decisions.
- Recorded vote required for procedural decisions
- Key group decisions, such as public dissemination of documents, are subject to approval by Modality Coordinating Committees
- Majority of participating members passes
- Negative votes must be discussed
- For recorded votes:
- Meeting attendee names and vote outcome will be recorded in minutes.